John Waas

A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer.

Afshin Dowlati, Kelly M. Robertson, Matthew M. Cooney et al. · PubMed · 2002 · 406 citations

Medicine, Oncology, Pharmacology +17

Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study

Suzanne Lentzsch, Amy K. O’Sullivan, Ryan Kennedy et al. · Blood · 2012 · 121 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Head and Neck Cancer: United Kingdom National Multidisciplinary Guidelines, Sixth Edition

Jarrod J. Homer, Stuart C. Winter, Elizabeth Abbey et al. · The Journal of Laryngology & Otology · 2024 · 50 citations · Full text

Medicine, Oncology, Otolaryngology +16

Novel Phase I Dose De-escalation Design Trial to Determine the Biological Modulatory Dose of the Antiangiogenic Agent SU5416

Afshin Dowlati, Kelly M. Robertson, Tomas Radivoyevitch et al. · Clinical Cancer Research · 2005 · 49 citations

Medicine, Oncology, Pharmacology +12

Successful management of life-threatening hemorrhage in a patient with synchronous lupus anticoagulant and factor VIII inhibitor

Hans A. Brings, John Waas, Keith R. McCrae et al. · Journal of Vascular Surgery · 2002 · 20 citations · Full text

Medicine, Hematology, Hemostasis +13